News
The diagnosis and treatment of glioblastoma during the 2008 financial crisis and the COVID-19 pandemic
The availability and ease of resources, and the time between the appearance of the primary tumor and the start of treatment are key to the patient’s prognosis, already poor in this disease.
An anti-diabetic and anti-inflammatory diet before the disease may contribute to a better prognosis in breast cancer survivors
A study led by researchers from the Nutrition and Cancer research group of the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) examined the relationship between dietary patterns before breast cancer diagnosis and the survival of these patients.
Great success of the 6th sLHam of women scientists
With the Barradas auditorium full, the 6th IDIBELL sLHam of female scientists was a total success. This year the sLHameres were Sandra Acosta, Begoña Arán, Lidia Franco, Núria Lloberas, Patricia Prada and Gemma Via, Fatima Akhtar and Paula Barrios, who, in a five-minute informative talk, explained their career in the scientific world, the challenges they have been overcoming and the motivations that have helped them to do so.
The discovery of an operable lesion in the brain makes it possible to control epileptic seizures triggered by eating act with surgery
A study led by the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB) has discovered an encephalocele in the right temporal pole of the brain in some of patients.
M Carolina Florian new ICREA Research Professor
Dra. M Carolina Florian, group leader at IDIBELL, has been appointed as an ICREA Research Professor. ICREA, the Catalan Institution for Research and Advanced Studies, offers permanent, tenured positions to the most talented and extraordinary scientists and academics to come and work in Catalonia. Over the years these positions have become a synonym for global academic excellence.
Two IDIBELL teams are granted two research projects on personalized medicine
Two researchers from IDIBELL will lead two multicenter research projects on precision personalized medicine: The PRECISION-ILD project lead by Dr Maria Molina (IDIBELL and Bellvitge University Hospital) and IMPaCT_VUSCan project, led by Dr Conxi Lázaro (IDIBELL and Catalan Oncology Institute). Both projects will last for three years, are financed by the Next Generation EU funds and have bee assigned by the Health Institute Carlos III (ISCIII) in a specific call on personalized medicine.
The 6th IDIBELL sLHam of women scientists will claim the role of women and girls in science
The event will be in the Barradas Auditorium in L’Hospitalet de Llobregat on Friday, February 10, at 7 p.m. The 6th sLHam incorporates a novelty: Together with six woman scientists from IDIBELL, two junior sLHamers from the Bellvitge Institute will participate.
New treatment options are opening up in the field of cutaneous lymphomas thanks to an immunotherapy-based drug
According to the results, brentuximab vedotin is effective and safe for some rare types of cutaneous T-cell lymphomas (LCCT)
A group of excellence composed of IDIBELL researchers and Cardiology professionals from the HUB joins the CIBER of Cardiovascular Diseases
The group linked to IDIBELL investigates personalized precision strategies for the interdisciplinary approach to heart failure in its evolutionary phases. Their research will contribute to the objective of the CIBERCV: reduce the impact of cardiovascular diseases and develop actions of excellence in translational cardiovascular research and training.